ADXN.SW Addex Therapeutics (SIX) pre-market CHF0.0564 vol 1.51M: watch liquidity
ADXN.SW stock shows heavy pre-market flow with 1,507,704 shares traded and price CHF0.0564. The jump to CHF0.0564 (up 2.92%) comes on a relative volume of 8.01, making Addex Therapeutics Ltd (ADXN.SW) one of the most active names on the SIX pre-market list. Traders should note the intraday range CHF0.0524–CHF0.0588, a 50-day average of CHF0.05639, and a 200-day average of CHF0.05826 for context.
Pre-market trading snapshot: ADXN.SW stock
Pre-market action shows ADXN.SW stock opened at CHF0.0524 and is trading at CHF0.0564 with 1,507,704 shares so far. Volume is well above the 20-day average (186,175), which signals short-term liquidity and higher trading interest. The intra-day high is CHF0.0588 and low CHF0.0524, giving active traders a clear short-term range to watch.
Catalysts and news flow
There is no company press release this morning, but recent licensing partnerships and program status for Dipraglurant remain the backdrop for Addex Therapeutics Ltd. We link the company site for filings and pipeline details: Addex Therapeutics. Market reactions are likely driven by trading flows and biotech sector momentum rather than fresh earnings data.
Valuation and financial metrics for ADXN.SW stock
Addex reports EPS -0.06 and an unusual PE -0.94, reflecting development-stage losses. Market capitalization is CHF8,509,175.00 with 150,871,899 shares outstanding. Key ratios: PB 1.07, price/sales 61.37, and current ratio 2.01, which point to a small-cap biotech with thin revenues and funded runway concerns. These metrics help explain high volatility and speculative trading.
Technical, liquidity and sector signals
Technically, ADXN.SW shows RSI 39.23 and ADX 42.37, indicating a strong trend but near-oversold momentum. The stock’s 50-day average (CHF0.05639) sits just under current price, suggesting a tight band. In the Healthcare sector, peers show three-month strength, which can lift small biotechs; still, liquidity swings matter more for ADXN.SW given its low market cap and large intraday volume.
Meyka AI grade and forecast
Meyka AI rates ADXN.SW with a score out of 100: 63.01 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects Monthly CHF0.06 (+6.38% vs CHF0.0564), Quarterly CHF0.08 (+41.84%), and Yearly CHF0.04487 (-20.45%). Forecasts are model-based projections and not guarantees.
Risks, opportunities and trading strategy
Short-term opportunity rests on pre-market liquidity and potential re-rating if clinical or partner updates arrive. Major risks include development-stage losses, limited free cash flow, and small-cap liquidity squeeze. For active traders, set tight stops and size positions to account for high volatility and low market cap exposure in the Swiss Biotechnology sector.
Final Thoughts
ADXN.SW stock is a most-active pre-market mover on the SIX due to unusually high volume (1,507,704) and a small market cap (CHF8,509,175.00). Our technical read shows momentum pressure but a clear intraday range (CHF0.0524–CHF0.0588) suitable for short-term trades. Meyka AI’s forecast shows a near-term target of CHF0.06 (+6.38%) and a quarterly model target of CHF0.08 (+41.84%), while a one-year projection points to CHF0.04487 (-20.45%). Investors should weigh the HOLD grade (B, score 63.01) against binary clinical and partnership outcomes. For traders, manage risk tightly and monitor announcements from Addex and sector peers; for longer-term investors, watch cash runway and development milestones before increasing exposure.
FAQs
What drives the pre-market move in ADXN.SW stock?
The pre-market move is volume-driven: 1,507,704 shares traded versus average 186,175. Large relative volume and biotech sector momentum, rather than a new corporate release, are the primary drivers.
What are Meyka AI’s short-term price targets for ADXN.SW stock?
Meyka AI projects Monthly CHF0.06 (+6.38%) and Quarterly CHF0.08 (+41.84%) versus the current CHF0.0564. These are model outputs, not guarantees.
Is ADXN.SW stock a buy for long-term investors?
Meyka AI assigns a B (HOLD) grade based on sector and financials. Long-term buyers should await clearer clinical progress or stronger cash metrics before allocating a larger position.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
